Skip to main content
OpenTrials
Completed

NCT Number: NCT04582474

Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso

The Integrated Management of Childhood Illness (IMCI) guideline has been implemented in Burkina Faso and is used across primary health facilities to assess children under the age of 5 years. A part from a rapid diagnostic test (RDT) for malaria, no other point of care in vitro diagnostic tests are widely used to improve disease diagnosis and inform treatment decisions. Dengue fever has been reported in Burkina Faso since 1925 and the recent epidemics in 2016 and 2017 have prompted the government to validate and deploy a clinical management algorithm for Dengue and a case reporting process to support surveillance for a targeted response.

The organisation Terre des hommes has digitalised IMCI and implemented the module through its Integrated electronic Diagnosis Approach (IeDA) programme across primary health care centers (PHCs) in the country with proven impact on clinical care and proven reduction in antibiotic prescriptions. Many recognize the need to update the IMCI guideline with current evidence. However this is challenging and may require large clinical trials. The advantage of electronic clinical decision support systems is plural: they improve quality of care through increased adherence and feedback information to the system; they strengthen surveillance systems by connecting relevant patient related data and provide geo-tagged coordinates for targeted responses; and they can become evidence-adaptive.

An electronic module of the Burkina Faso Dengue clinical management guideline accompanied with dengue rapid diagnostic tests has the potential to improve the diagnosis of non-malaria fevers in particular during "dengue seasons" and improve the efficiency of surveillance for this disease.

In this study, the investigators aim to assess the usability and the performance of the dengue module for patient management in primary health care facilities.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre de Santé et de Promotion Sociale (Sandogo), Ouagadougou, District Boulmiougou, Burkina Faso

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Older than 6 month
  • Presentation with fever (axillary temperature ≥ 37,5⁰C) or history of fever for 2-7 days without localizing signs of another pathology such as malaria diagnosed by RDT
  • Malaria diagnosis: negative malaria RDT performed at the the study site by a nurse as part of the routine consultation, or a positive malaria RDT with antimalarial treatment failure

Exclusion criteria

  • Neonates (0-2 months) and children ≤ 6 month for operational reasons such as difficulties with blood draw
  • Patients with severe disease requiring urgent care

Treatment and study plan

Dengue module and rapid diagnostic tests

Other

Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines

Primary outcomes

  1. Point estimates of the percentage of dengue consultations performed using the dengue module, with 95% confidence intervals

    Time frame: 4 months

    This outcome will be evaluated by reporting the ratio of dengue consultations performed using the dengue module over the total number of consultations, together with a 95% confidence interval based on Wilson's score method.

  2. Evaluation of the adherence to the different steps of the module

    Time frame: 4 months

    This outcome will be evaluated by the percentage ratio of dengue module steps adhered by patients over the total number of patients at each step.

Secondary outcomes

  1. Estimate of the operational characteristic, Efficacy, of the dengue module: percentage of forms emitted from the module received in the surveillance system

    Time frame: 4 months

  2. Estimate of the operational characteristic, Timeliness, of the dengue module: percentage of forms that are received by the surveillance system on time, as defined by the national surveillance system.

    Time frame: 4 months

  3. Estimate of operational characteristic, Completeness, of the dengue module: percentage of fields that are completed.

    Time frame: 4 months

  4. Positive predictive value of dengue rapid diagnostic test

    Time frame: 4 months

    Polymerase chain reaction results will be used as the reference test.

Sponsors and collaborators

Lead sponsor

Foundation for Innovative New Diagnostics, Switzerland

Other

Collaborators

  • Ministry of Health, Burkina Faso
  • Terre des hommes, Burkina Faso & Switzerland

Registry information

Official study title

Demonstration of an Electronic Clinical Decision Support Module for Dengue Case Management and Reporting in Burkina Faso

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Oct 9, 2020
Registry last updated
Sep 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.